Condition: Breast Cancer · Sponsor: Hoffmann-La Roche
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
This description comes directly from the study's public registry record.
Reference Study ID Number: WO46063 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Los Angeles Cancer Network | Los Angeles, California, United States | Recruiting |
| Astera Cancer Care East Brunswick | East Brunswick, New Jersey, United States | Recruiting |
| Instituto de Oncologia de Rosario | Rosario, Santa Fe Province, Argentina | Recruiting |
| Centro Oncologico Korben | Ciudad Autonoma Buenos Aires, Argentina | Recruiting |
| Hospital Privado - Centro Medico de Córdoba | Córdoba, Argentina | Recruiting |
| Centro Oncologico Riojano Integral (CORI) | La Rioja, Argentina | Recruiting |
| Hospital Provincial del Centenario | Rosario, Argentina | Recruiting |
| Centro Oncológico de Excelencia | San Juan, Argentina | Recruiting |
| Blacktown Hospital | Blacktown, New South Wales, Australia | Recruiting |
| Coffs Harbour Health Campus | Coffs Harbour, New South Wales, Australia | Recruiting |
| Bendigo Cancer Centre | Bendigo, Victoria, Australia | Recruiting |
| Cliniques Universitaires St-Luc | Brussels, Belgium | Recruiting |
+ 18 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07368998